Guided Therapeutics, Inc.

185 articles with Guided Therapeutics, Inc.

• After Meeting with FDA, Guided Therapeutics to Start Study in Support of its Application for FDA Approval

  10/21/2020

  Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless cervical cancer detection test based on its patented biophotonic technology, announced today the successful outcome of its October 14, 2020 meeting with FDA. The purpose of the meeting was to finalize the protocol (procedure) for its n

• Guided Therapeutics Ships LuViva Devices and Disposables for Chinese FDA Pivotal Clinical Trial

  9/14/2020

  Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced that it had shipped four LuViva Advanced Cervical Scan systems and associated disposables to its Chinese co-manufacturing partner and distributor for China, Shandong Yaohua Medical Instrument Corporation. Shandon

• Guided Therapeutics Continues FDA Progress and Schedules Key Meeting to Finalize Clinical Study Protocol for the LuViva® Advanced Cervical Scan

  8/27/2020

  Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless cervical cancer detection test based on its patented biophotonic technology, announced that it will meet with the FDA to finalize the protocol for its clinical study in support of its Premarketing Application for the LuViva® Advanced Cervical Scan

• Guided Therapeutics Submits Clinical Study Protocol to U.S. FDA for LuViva® Advanced Cervical Scan

  7/28/2020

  Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless cervical cancer detection test based on its patented biophotonic technology, announced today that it had submitted its protocol to FDA for a clinical study to support marketing of the LuViva® Advanced Cervical Scan in the United States. Under FDA’s Investigational Device Exemption guidelines, the Agency typically responds to companies

• Guided Therapeutics Successfully Uplists to Over the Counter Venture Market from Pink Sheets

  7/22/2020

  Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that its common stock is now listed for trading on the Over the Counter Venture Market (OTCQB) Exchange. The stock formerly traded on the Pink Sheets. “The uplisting to the OTC Venture Market provides our current and potential shareholders with greater trans

• Guided Therapeutics LuViva Advanced Cervical Scan Awarded New CE Mark with Expanded Claims

  7/1/2020

  Guided Therapeutics, Inc. (Pink Sheets: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced that its flagship product, the LuViva Advanced Cervical Scan, had received a new CE Mark through its European contract manufacturer, Newmars Technologies, Kf

• Guided Therapeutics Announces Completion of a $1.5 Million Financing to Accelerate 2020 Business Plan

  6/30/2020

  Guided Therapeutics, Inc. (Pink Sheets: GTHP), the maker of a rapid and painless cervical cancer detection test based on its patented biophotonic technology, announced today that it had completed a Series E Convertible Preferred Stock Offering in the amount of $1.5 Million. The financing was led by Rosalind Advisors, Inc. and Fieldhouse Capital Management, Inc. (FCMI), and included a combination of current and new institut

• Guided Therapeutics and Chinese Partner Shandong Yaohua Medical Instrument Corporation Complete Key Step in Chinese FDA Approval Process

  5/28/2020

  Guided Therapeutics and Chinese Partner Shandong Yaohua Medical Instrument Corporation Complete Key Step in Chinese FDA Approval Process  

• Guided Therapeutics and FDA Meet; Agree on Path Forward in Approval Process

  4/30/2020

  Guided Therapeutics, Inc. (Pink Sheets: GTHP), the maker of a rapid and painless cervical cancer detection test based on its patented biophotonic technology, announced today it had held a scheduled teleconference on April 28, 2020 with the US FDA as the next step for obtaining sales and marketing approval of its LuViva Advanced Cervical Scan. As a previous step, the Company filed on February 17, 2020 its FDA Pre-

• Guided Therapeutics Files Pre-Submission Document with U.S. FDA Detailing Clinical Plan to Support Approval

  2/18/2020

  Guided Therapeutics, Inc. announced it had achieved significant progress with the U.S. FDA in restarting its efforts for sales and marketing approval of its LuViva Advanced Cervical Scan.

• Guided Therapeutics Plans Growth for 2020 After Closing Significant Financing

  1/28/2020

  Guided Therapeutics, Inc., the maker of a rapid and painless cervical cancer detection test based on its patented biophotonic technology, announced the Company’s plans for 2020.

• Guided Therapeutics Raises Funds Aimed at Increasing International Sales and Restarting US FDA Approval Process

  1/6/2020

  Guided Therapeutics, Inc. (Pink Sheets: GTHP), the maker of a rapid and painless cervical cancer detection test based on its patented biophotonic technology, announced today the closing of two separate investments: The first, a Convertible Note issued to Auctus Fund, LLC for $2.4 Million, occurs in three tranches.

• Guided Therapeutics Reports New Progress with Chinese FDA and Increased Sales Forecast from Shandong Medical Device Technology Company

  6/5/2019

  The study is expected to begin this summer and be completed within three months, after which Shandong will file final paperwork for approval.

• Guided Therapeutics Receives $2.5 Million Purchase Order from Chinese Partner Shandong Medical Device Technology Company

  4/2/2019

  The Class 2 designation is expected to result in a faster approval than a Class 3 designation.

• Guided Therapeutics Reports Significant Progress in Eliminating Variable Rate Convertible Loans and Restructuring Capitalization; Announces Reverse Stock Split

  3/28/2019

  Guided Therapeutics, Inc. (Pink Sheets: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, today announced it has successfully closed out variable rate convertible loans with three lenders and reached preliminary agreements with two other lenders to exchange their variable rate convertible notes for cash and fixed rate equity once a significant financing of the Company occurs. In return, the two lenders have agreed to suspend conversions

• Central/Eastern European/Russian Distributor Expands LuViva Program by Signing Manufacturing, Supply and Royalty Agreement; Projects Purchases of $30 Million over 5 Years

  12/18/2018

  Guided Therapeutics, Inc. (PINK SHEETS: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced that it has signed a limited Manufacturing, Supply and Royalty Agreement with its Central/Eastern European/Russian distribution partner Newmars Technologies, Inc.

• Guided Therapeutics Reports Significant Reductions in Debt and Operating Expenses

  12/4/2018

  Guided Therapeutics, Inc. (PINK SHEETS: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, has made significant strides toward reducing its debt and ongoing operating expenses.

• Indonesia Places Significant Order for New LuViva Devices and Single-Use Cervical Guides

  11/26/2018

  The four additional units bring the total sold and placed in Indonesia to 31, with approximately 1/3 of these units shipped in the last year.

• Chinese Distributor/Manufacturer Completes $1 Million Payment to Guided Therapeutics and Orders Parts in Anticipation of Launch Next Year

  11/13/2018

  Shandong completed the last of its $1 million dollars in payments to Guided Therapeutics under the terms of the agreement between the two companies.

• Guided Therapeutics Announces Extension of Distribution Agreement for Eastern Europe and Russia

  11/8/2018

  ​Minimum Orders in Contract to Total More than $20 Million.